NEW ANTIVIRAL DRUG

CONCENTRATION DISTRIBUTION MEASURING METHOD OF BORON FOR BNCT USING MRI AND TREATMENT PLANNING METHOD OF BNCT

The present invention relates to a boron concentration distribution measuring method for BNCT capable of measuring boron concentration and anatomical imaging of a patient accurately by only using a magnetic resonance imaging (MRI); and a treatment planning method of BNCT. The present invention includes: (a) a step (S10) of measuring boron concentration and anatomical imaging of a patient from magnetic resonance (MR) data; (b) a step (S20) of extracting a boron concentration change prediction parameter of a patient and predicting a concentration by time; (c) a step (S30) of calculating and verifying a boron distribution prediction value estimated by spectrum analysis and boron imaging; and (d) a step (S40) of deriving optimal time of BNCT treatment from the verified result. COPYRIGHT KIPO 2018 (AA) Anatomical image (BB) Measure boron concentration (CC) Determine position of tumor/blood vessel/normal tissue (DD) Measure concentration change per hour of boron (Blood vessel, Tumor, Normal cell ...

Nitroimidazole derivative and diagnostic imaging agent containing the same

N-ACETYL-3-FLUORO-NEURAMINIC ACID DERIVATIVES AND PREPARATION THEREOF

N-ACETYL-3-FLUORO-NEURAMINIC ACID DERIVATIVES AND PREPARATION THEREOF

NEW ANTIVIRAL DRUG

METHOD FOR MEASURING CONCENTRATION DISTRIBUTION OF BORON FOR BNCT USING MRI, AND TREATMENT PLANNING METHOD FOR BNCT

Disclosed are a method of measuring concentration distribution of boron for boron neutron capture therapy (BNCT) using magnetic resonance imaging (MRI) alone and a treatment planning method for BNCT. The methods include (a) acquiring an anatomical image of a patient and measuring a boron concentration from magnetic resonance (MR) data, (b) extracting a boron concentration change prediction parameter of the patient and predicting the concentration over time, (c) calculating and verifying a boron distribution prediction value estimated by boron imaging and spectral analysis, and (d) deriving an optimal time for BNCT based on the verified results. 1. A treatment planning method for BNCT (Boron Neutron Capture Therapy) using MRI (Magnetic Resonance Imaging) , comprising:(a) acquiring an anatomical image of a patient and measuring a boron concentration from magnetic resonance (MR) data;(b) extracting a boron concentration change prediction parameter of the patient and predicting a concentration over time;(c) calculating and verifying a boron distribution prediction value estimated by boron imaging and spectral analysis; and(d) deriving an optimal time for BNCT based on a verified result.2. The treatment planning method for BNCT of claim 1 , wherein in step (a) claim 1 , the boron concentration is measured through magnetic resonance spectroscopy of boron.3. The treatment planning method for BNCT of claim 1 , wherein in step (b) claim 1 , when a time-dependent change in the boron concentration is measured using magnetic resonance spectroscopy of boron claim 1 , the boron concentration is measured at least four times for 1 hr or more.4. A method of measuring boron concentration distribution for BNCT claim 1 , comprising obtaining a concentration distribution of boron by acquiring an anatomical image of a patient and measuring a boron concentration from MR data and combining two pieces of information.5. The method of claim 4 , wherein the boron concentration over time is ...

Metallic heating element

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

DERIVED FROM NITROIMIDAZOL AND AGENT OF DIAGNOSIS IMAGE FORMER THAT CONTAINS IT.

Un derivado de nitroimidazol representado mediante la siguiente fórmula (1): [en la que R1 representa un átomo de hidrógeno o un grupo alcanoilo C1-C4; y X representa un átomo de flúor o un isótopo del mismo]. A nitroimidazole derivative represented by the following formula (1): [wherein R1 represents a hydrogen atom or a C1-C4 alkanoyl group; and X represents a fluorine atom or an isotope thereof].

Nitroimidazole derivative and diagnostic imaging agent containing the same

A nitroimidazole derivative represented by formula (1): [wherein R1 represents a hydrogen atom or a C1-C4 alkanoyl group; and X represents a fluorine atom or an isotope thereof], and a diagnostic imaging agent containing the derivative as an active ingredient. The derivative enables imaging of the ischemic sites of a circulatory organ or imaging of cancer cells, and thus the derivative can provide information about the position and the amount of the ischemic sites or the cancer cells. Therefore, the derivative contributes to selection of appropriate treatment of ischemia or cancer.

N-acetyl-3-fluoro-neuraminic acid derivatives and preparation of same

N-acetyl-3-fluoro-neuraminic acid derivatives and preparation thereof

ABSTRACT OF THE DISCLOSURE This invention relates to novel derivatives of N-acetyl-3-fluoro-neurminic acid derivatives (I) and preparation thereof. The compound (I) can be synthesized by reacting a solution of alkyl 5-acetamido-2,6-anhydro-4,7,8,9-tetra-O-acetyl-2,3,5-trideoxy-D-glycero-D-galacto-2-enonate with (i) an inert gas containing fluorine or (ii) acetylhypo-fluorite obtained by passing the inert gas containing fluorine through a mixture of acetic acid/acetate by passing thereinto, and then removing a solvent and apply-ing the residue through a silica gel column chromatogra-phy.

Method for measuring concentration distribution of boron for BNCT using MRI, and treatment planning method for BNCT

Disclosed are a method of measuring concentration distribution of boron for boron neutron capture therapy (BNCT) using magnetic resonance imaging (MRI) alone and a treatment planning method for BNCT. The methods include (a) acquiring an anatomical image of a patient and measuring a boron concentration from magnetic resonance (MR) data, (b) extracting a boron concentration change prediction parameter of the patient and predicting the concentration over time, (c) calculating and verifying a boron distribution prediction value estimated by boron imaging and spectral analysis, and (d) deriving an optimal time for BNCT based on the verified results.

Nitroimidazolderivate und diese enthaltende diagnostische bilderzeugungsmittel